Considerations in the management of younger patients with colorectal cancer.


Journal

Clinical advances in hematology & oncology : H&O
ISSN: 1543-0790
Titre abrégé: Clin Adv Hematol Oncol
Pays: United States
ID NLM: 101167661

Informations de publication

Date de publication:
Jun 2021
Historique:
entrez: 15 3 2022
pubmed: 16 3 2022
medline: 18 3 2022
Statut: ppublish

Résumé

The incidence of colorectal cancer in patients ages 18 to 49 years has increased by 51% throughout the past 3 decades. In the United States, recent guidelines lowered the initial screening age to 45 years. More than 75% of colorectal tumors in younger patients are diagnosed based on the onset of symptoms, such as rectal bleeding, abdominal pain, weight loss, or anemia. In most cases, these individuals do not have a family history of colorectal cancer. On average, the diagnosis of colorectal cancer in younger patients occurs from 6 months to several years after symptoms first arise. As a result, younger patients diagnosed with colorectal cancer tend to present with advanced disease. If a younger patient does not have any contraindications, it is appropriate to consider treatment with a triplet chemotherapy combined with a biologic. The impact of treatment can be greater for younger patients than for older individuals. Even mild or moderate toxicities can strongly impact their daily lives. Younger patients with colorectal cancer are likely to have a higher risk for long-term treatment-related sequelae, particularly because they tend to present with advanced disease and will receive therapy for a prolonged period.

Identifiants

pubmed: 35289787

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-20

Auteurs

Joleen M Hubbard (JM)

Mayo Clinic, Rochester, Minnesota.

Cathy Eng (C)

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

Chiara Cremolini (C)

Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
GONO Foundation, Genoa, Italy.

John L Marshall (JL)

Division of Hematology/Oncology, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC.
Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH